Ph3 Randomized Open-label Study of JNJ-78278343 + Docetaxel Versus Docetaxel for mCRPC
Phase III Clinical Trial
A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T Cell-redirecting agent targeting Human Kallikrein 2 with Docetaxel Versus Docetaxel for Metastatic Castration-Resistant Prostate Cancer (78278343PCR3003 (KLK2-PASenger))